Estrogen Receptors and Enzymes Involved in Estrogen Synthesis as Breast Cancer Treatment Targets
Barbara Licznerska, Hanna Szaefer, Hanna Sobierajska, Wanda Baer-Dubowska · 2026
Read Estrogen Receptors and Enzymes Involved in Estrogen Synthesis as Breast Cancer Treatment Targets by Barbara Licznerska, Hanna Szaefer, Hanna Sobierajska, Wanda Baer-Dubowska (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13466369.txt.
Description
Licznerska and co-authors review the two fronts of hormonal attack on breast cancer: blocking estrogen's receptor and stopping estrogen's manufacture. Their 2026 paper notes about seventy percent of breast cancers depend on estrogen. Receptor modulators work well until resistance develops, and they are useless in triple-negative disease, leaving the synthesis enzymes as the complementary target set.
Three enzymes anchor the review. Aromatase inhibitors are already clinical mainstays. Sulfatase and the 17-beta-hydroxysteroid dehydrogenases, which activate weaker estrogen forms, remain under intensive investigation as drug targets. The authors summarise recent modulators and inhibitors across both the receptor and all three enzymes, a combination few reviews attempt together. Their perspective weighs where dual targeting might overcome resistance and whether any of these routes can eventually reach the triple-negative gap.
Catalog record
| CREATOR | Barbara Licznerska, Hanna Szaefer, Hanna Sobierajska, Wanda Baer-Dubowska |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |